NASDAQ:IRWD Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis $4.51 -0.15 (-3.22%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$4.49▼$4.7650-Day Range$4.05▼$7.0452-Week Range$3.79▼$15.70Volume1.64 million shsAverage Volume3.31 million shsMarket Capitalization$705.95 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ironwood Pharmaceuticals alerts: Email Address Ironwood Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside232.6% Upside$15.00 Price TargetShort InterestHealthy9.00% of Float Sold ShortDividend StrengthN/ASustainability-2.94Upright™ Environmental ScoreNews Sentiment0.89Based on 4 Articles This WeekInsider TradingSelling Shares$185,514 Sold Last QuarterProj. Earnings Growth33.33%From $0.36 to $0.48 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.37 out of 5 starsMedical Sector111th out of 910 stocksPharmaceutical Preparations Industry40th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingIronwood Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageIronwood Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Ironwood Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.00% of the float of Ironwood Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIronwood Pharmaceuticals has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Ironwood Pharmaceuticals has recently decreased by 11.39%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIronwood Pharmaceuticals does not currently pay a dividend.Dividend GrowthIronwood Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIronwood Pharmaceuticals has received a 39.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Linaclotide" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ironwood Pharmaceuticals is -2.94. Previous Next 2.7 News and Social Media Coverage News SentimentIronwood Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Ironwood Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for IRWD on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Ironwood Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ironwood Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $185,514.00 in company stock.Percentage Held by Insiders12.90% of the stock of Ironwood Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Ironwood Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Ironwood Pharmaceuticals are expected to grow by 33.33% in the coming year, from $0.36 to $0.48 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ironwood Pharmaceuticals is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ironwood Pharmaceuticals is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Ironwood Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD)Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Read More IRWD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRWD Stock News HeadlinesAugust 15, 2024 | insidertrades.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Insider Sells $42,315.70 in StockSeptember 2, 2024 | insidermonkey.comIronwood Pharmaceuticals, Inc. (IRWD): The Best Multibagger Penny Stock of 2025?September 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. September 1, 2024 | americanbankingnews.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives $15.00 Consensus Price Target from AnalystsAugust 31, 2024 | finance.yahoo.comIronwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare ConferenceAugust 15, 2024 | finance.yahoo.comAnalysts Have Just Cut Their Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Revenue Estimates By 13%August 10, 2024 | finance.yahoo.comIronwood Pharmaceuticals, Inc. Reported A Surprise Loss, And Analysts Have Updated Their ForecastsAugust 10, 2024 | markets.businessinsider.comIronwood Pharmaceuticals: Hold Rating Amidst Financial and Market HeadwindsSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 10, 2024 | seekingalpha.comIronwood Pharmaceuticals, Inc. (IRWD) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | seekingalpha.comIronwood Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call PresentationAugust 8, 2024 | markets.businessinsider.comIRWD Stock Earnings: Ironwood Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024August 8, 2024 | markets.businessinsider.comIronwood Pharmaceuticals A earnings: here's what to expectAugust 8, 2024 | msn.comIronwood Pharmaceuticals Non-GAAP EPS of $0.00 misses by $0.14, revenue of $94.4M misses by $12.6MAugust 8, 2024 | finance.yahoo.comIronwood Pharmaceuticals Reports Second Quarter 2024 ResultsAugust 6, 2024 | markets.businessinsider.comCraig-Hallum Keeps Their Buy Rating on Ironwood Pharma (IRWD)August 1, 2024 | finance.yahoo.comIronwood Pharmaceuticals (NASDAQ:IRWD) shareholders have endured a 49% loss from investing in the stock three years agoJuly 25, 2024 | stockhouse.comIronwood Pharmaceuticals to Host Second Quarter 2024 Investor Update CallSee More Headlines Receive IRWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:IRWD CUSIP46333X10 CIK1446847 Webwww.ironwoodpharma.com Phone(617) 621-7722Fax617-494-0480Employees220Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$22.00 Low Stock Price Target$4.00 Potential Upside/Downside+232.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($6.79) Trailing P/E RatioN/A Forward P/E Ratio12.53 P/E GrowthN/ANet Income$-1,002,240,000.00 Net Margins2.30% Pretax Margin21.50% Return on Equity-6.37% Return on Assets4.61% Debt Debt-to-Equity RatioN/A Current Ratio3.92 Quick Ratio3.92 Sales & Book Value Annual Sales$400.57 million Price / Sales1.76 Cash FlowN/A Price / Cash FlowN/A Book Value($2.01) per share Price / Book-2.24Miscellaneous Outstanding Shares156,529,000Free Float136,337,000Market Cap$705.95 million OptionableOptionable Beta0.52 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Thomas A. McCourt (Age 67)CEO & Director Comp: $1.61MMr. Sravan Kumar Emany (Age 46)Senior VP, Principal Financial Officer & CFO Comp: $913.88kMr. John Minardo (Age 48)Senior VP, Chief Legal Officer & Secretary Comp: $814.41kDr. Michael Shetzline M.D. (Age 65)Ph.D., Chief Medical Officer, Senior VP and Head of Research & Drug Development Comp: $860.45kMr. Andrew Davis (Age 37)Senior VP & Chief Business Officer Comp: $824.36kMr. Ronald Silver (Age 41)Corporate Controller & Principal Accounting Officer Mr. Marcel MoulaisonVice President of Technical OperationsGreg MartiniVice President of Strategic Finance & Investor RelationsMs. Beth CalitriHead of Corporate Communications & Media RelationsMr. Mike NanfitoVice President of Sales & Sales ExcellenceMore ExecutivesKey CompetitorsIGM BiosciencesNASDAQ:IGMSCryoportNASDAQ:CYRXZentalis PharmaceuticalsNASDAQ:ZNTLKura OncologyNASDAQ:KURABausch Health CompaniesNYSE:BHCView All CompetitorsInsiders & InstitutionsStonepine Capital Management LLCBought 48,012 shares on 8/21/2024Ownership: 0.031%Algert Global LLCBought 14,200 shares on 8/16/2024Ownership: 0.009%The Manufacturers Life Insurance Company Sold 3,013 shares on 8/15/2024Ownership: 0.049%Dark Forest Capital Management LPBought 8,557 shares on 8/15/2024Ownership: 0.039%AXA S.A.Sold 3,258 shares on 8/15/2024Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions IRWD Stock Analysis - Frequently Asked Questions How have IRWD shares performed this year? Ironwood Pharmaceuticals' stock was trading at $11.44 on January 1st, 2024. Since then, IRWD stock has decreased by 60.6% and is now trading at $4.51. View the best growth stocks for 2024 here. How were Ironwood Pharmaceuticals' earnings last quarter? Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by $0.20. Ironwood Pharmaceuticals's revenue was down 28.0% compared to the same quarter last year. What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO? 7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are Ironwood Pharmaceuticals' major shareholders? Top institutional investors of Ironwood Pharmaceuticals include Pacer Advisors Inc. (5.69%), Renaissance Technologies LLC (5.48%), Armistice Capital LLC (4.98%) and LSV Asset Management (3.88%). Insiders that own company stock include Thomas A Mccourt, Mark G Currie, Jason Rickard, Michael Shetzline, Sravan Kumar Emany, Minardo John, Andrew Davis, Julie Mchugh, Jon R Duane, Ronald Silver, Catherine Moukheibir and Marla L Kessler. View institutional ownership trends. How do I buy shares of Ironwood Pharmaceuticals? Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ironwood Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ironwood Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH) and Allergan (AGN). This page (NASDAQ:IRWD) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IRWD Stock Alerts